Azipin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Azipin

What is Azipin?

Azipin is an antibiotic medication belonging to the macrolide class. It contains the active substance azithromycin, which is used to treat various types of infections caused by bacteria. Unlike medications used for viral infections such as the common cold or flu, Azipin specifically targets bacterial growth and survival.

Mechanism of Action

The medication works by interfering with the protein synthesis of susceptible bacteria. By binding to the bacterial ribosome, it prevents the bacteria from producing essential proteins required for their growth and multiplication. This action effectively inhibits the spread of the infection, allowing the body's immune system to eliminate the remaining bacteria.

Common Applications

Azipin is utilized in the management of several bacterial conditions, including:

  • Respiratory tract infections: Such as bronchitis, pneumonia, and sinus infections.
  • Throat and tonsil infections: Including pharyngitis and tonsillitis.
  • Skin and soft tissue infections: Treatment of uncomplicated skin structure infections.
  • Ear infections: Specifically acute otitis media.
  • Genitourinary infections: Treatment of certain sexually transmitted infections caused by specific bacteria.

Characteristics

Azipin is known for its pharmacological profile, which allows it to remain in the body's tissues for an extended period. This characteristic often results in shorter treatment courses compared to other classes of antibiotics. It is designed to be stable in the presence of gastric acid, making it suitable for oral administration.

Regulatory References

  1. Azithromycin Drug Information - MedlinePlus

What side effects are possible with Azipin?

Possible Side Effects and Safety Information

The safety profile of Azipin is based on documented adverse reactions and specific safety warnings from regulatory documents.

Frequency-Classified Adverse Reactions

The most common side effects (affecting 1 in 100 to less than 1 in 10 patients) typically involve the gastrointestinal system and include diarrhea, nausea, abdominal pain, and vomiting. Less common reactions may affect the nervous system (e.g., dizziness, headache) or the skin (e.g., rash, photosensitivity).

Serious and Clinically Significant Adverse Reactions

Official regulatory sources highlight the potential for severe, life-threatening adverse reactions, though they are rare. These include:

  • Cardiovascular Risks: Azipin can prolong the QT interval on the heart's electrical rhythm, carrying a risk of developing a serious, irregular heart rhythm known as Torsades de Pointes, which may be fatal.
  • Liver Toxicity (Hepatotoxicity): Cases of abnormal liver function, cholestatic jaundice, hepatitis, and in rare instances, fatal hepatic failure or hepatic necrosis have been reported.
  • Severe Allergic Reactions: Severe hypersensitivity reactions such as anaphylaxis, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis (TEN) have been documented. These reactions can be life-threatening and may recur even after the medicine is stopped.

Population-Specific Safety Considerations

  • Neonates (up to 42 days of age): Use in this population has been associated with a specific risk of developing Infantile Hypertrophic Pyloric Stenosis (IHPS), a serious gastrointestinal blockage.
  • Elderly Patients: Older adults, particularly those with pre-existing heart conditions, may have an increased susceptibility to the heart rhythm risks (Torsades de Pointes).

Safety Restrictions and Limitations

Azipin is contraindicated (must not be used) in patients with a history of a known severe allergic reaction to Azipin, erythromycin, any macrolide, or ketolide drug, or in patients with a history of cholestatic jaundice or liver dysfunction associated with prior use of Azipin. Caution is required when using this medicine in individuals with pre-existing heart conditions that predispose them to rhythm abnormalities, such as known QT prolongation.

Overdose and Emergency Response

Overdose and When to Seek Help

Official government regulatory information defines the azithromycin (Azipin) overdose profile primarily by its immediate symptomatic effects and the required emergency response.

Documented Overdose Manifestations

Regulatory documents state that an overdose of azithromycin may lead to the following symptoms:

System Manifestations
Gastrointestinal Severe nausea, vomiting, and diarrhea
Systemic Prostration (extreme physical exhaustion or collapse)
Auditory Reversible hearing loss (documented in some cases)

Required Emergency Actions

Immediate medical attention is required in the event of an overdose or if overdose symptoms are experienced. Prompt professional assessment is necessary to manage systemic risks.

There is no specific antidote for azithromycin overdose. Management, as outlined in official labeling, is entirely symptomatic and supportive. Actions that may be administered by healthcare professionals include:

  • Administering medicinal (activated) charcoal.
  • Initiating gastric lavage (stomach irrigation).
  • Providing general supportive measures and symptomatic treatment for any distress or physiological imbalances.

Key Overdose Considerations

The primary concern in an overdose scenario is the need to manage the symptoms and monitor for cardiotoxicity, as azithromycin has been associated with prolongation of the QT interval. The official profile emphasizes rapid intervention to stabilize the patient and ensure comprehensive supportive care.

Therapeutic Uses of Azipin

Azipin: Main Uses and Benefits in Symptom Management

Azipin (Azithromycin) is a systemic antibiotic commonly used to help manage various bacterial infections and supports general well-being during symptomatic periods. The primary purpose is to address the bacterial cause of the illness, which supports the patient during difficult episodes by easing distress and assists with maintaining functional stability. It is indicated for conditions including certain bacterial infections of the ears, lungs, sinuses, throat, skin, and reproductive organs.

Therapeutic Scenarios and Symptom Relief

This medication is applied across domains where additional symptomatic support is needed for conditions presenting with systemic or localized discomfort. It is commonly used for infections such as community-acquired pneumonia, acute bacterial exacerbations of chronic bronchitis, acute otitis media, bacterial sinusitis, uncomplicated skin infections, and specific sexually transmitted diseases (STIs). Azipin is relevant for easing symptom clusters that may become intense or disruptive, like acute cough, fever, localized pain, and discharge.

In these scenarios where additional management of discomfort is required, the focus is on supportive relief, which helps maintain a sense of stability when symptoms are more noticeable. This supportive use helps improve day-to-day comfort during symptomatic periods and assists with maintaining functional stability, particularly in acute episodes and for conditions involving episodic or fluctuating manifestations where prophylaxis is needed.


Quick Fact Block

Quick Fact: Relief for Acute Infections Description
Symptom Areas Helps manage discomfort related to respiratory, skin/tissue, and ENT infections.
Clinical Context Commonly used during acute episodes when symptoms are driven by susceptible bacteria.
Primary Benefit Supports patients by addressing the bacterial cause, which contributes to easing the overall symptom load.

Regulatory References

  1. NIH MedlinePlus overview on Azithromycin

Eligibility and Restrictions for Use

Azipin (azithromycin) use is defined by specific regulatory criteria detailing when the medicine may be given and when it is formally restricted or prohibited.

Populations That Must Not Use Azipin

Azipin is contraindicated and must not be used by patients who have a known hypersensitivity or allergic reaction to azithromycin, erythromycin, any macrolide, or any ketolide antibiotic. Use is also prohibited in patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior use of azithromycin.

Specific Eligibility Restrictions

  • Pediatric Use: Safety and effectiveness have not been established for treating community-acquired pneumonia or acute otitis media in children under 6 months of age. For pharyngitis/tonsillitis, use is not established in children younger than 2 years of age.
  • Oral Therapy: Oral formulations are not recommended for treating pneumonia in patients judged inappropriate for oral therapy, such as those with risk factors like cystic fibrosis, nosocomial infections, or known bacteremia.
  • Liver Function: The drug should be used with caution in patients with impaired hepatic function. Use in patients with severe liver disease is generally not recommended in official guidelines.
  • Pregnancy/Lactation: Use during pregnancy is advised only if clearly necessary. A decision must be made to either discontinue nursing or discontinue the drug when administering to a nursing woman.

What should I know about interactions with other medicines?

Azipin Interactions with other medicines and products

This section outlines interactions with other medicines and products as officially documented in government regulatory sources, such as the FDA and EMA.

Contraindicated and High-Risk Combinations

Co-administration with Ergot Derivatives (e.g., Ergotamine, Dihydroergotamine) is not recommended due to the theoretical potential for ergotism. Azipin should also be avoided with other medications known to prolong the QT interval (a measure of heart rhythm), as this combination carries an additive risk for serious cardiac arrhythmias, including Torsades de Pointes.

Pharmacokinetic and Pharmacodynamic Interactions

Azithromycin does not significantly interact with the hepatic Cytochrome P-450 system (CYP), meaning it does not typically induce or inactivate these enzymes. However, it can affect certain drug transporters, such as P-glycoprotein.

Interacting Substance Official Regulatory Description
Digoxin May increase Digoxin serum concentrations; requires monitoring.
Warfarin Spontaneous reports suggest the potential for increased prothrombin time/INR; requires coagulation monitoring.
Nelfinavir Significantly increases Azipin serum concentrations ( C max and AUC); warrants close monitoring for known Azipin adverse reactions.
Antacids (Aluminum/Magnesium) Reduces Azipin's peak serum concentration ( C max). Must be taken at least 2 hours apart.
Food Increases C max of Azipin tablets (23%) and oral suspension (56%).

Population-Specific Notes

Caution is advised when Azipin is administered to patients with impaired hepatic function due to its primary route of elimination, as noted in regulatory documents.

Mechanism of Action

Azipin (Azithromycin) exerts its effect through a highly specific dual mechanism involving both direct microbial interference and host response modulation.

The core function centers on its action as a ribosomal inhibitor. The drug targets the bacterial 50S ribosomal subunit, attaching to the 23S rRNA to physically block the peptide exit tunnel . This precise molecular blockade prevents the elongation of necessary protein chains, halting the bacteria's ability to grow and replicate (bacteriostasis), thereby allowing the host's natural defenses to clear the static bacterial burden.

Beyond this, Azipin acts as an immunomodulator by accumulating within host immune cells. Inside these cells, it suppresses the activation of key inflammatory pathways, particularly the NF-κB signaling cascade. This mechanism limits the transcription and release of pro-inflammatory mediators like cytokines, contributing to the suppression of excessive inflammatory signaling and limiting inflammatory cell-mediated activity.

Dosage and Administration Information

How to Use Azipin: Official Administration Guidelines

Azipin (Azithromycin) is administered according to strict dosage regimens. The medication is primarily intended for Oral use, available as tablets, capsules, and suspensions. It is also approved for Intravenous (IV) infusion in acute care settings, and certain ophthalmic preparations are available for localized treatment. The medication must be taken as a single daily dose throughout the entire course, reflecting its long half-life.


Standard Dosage Patterns

Dosing schedules are highly standardized and depend on the specific treatment course:

  • 5-Day Course: Typically starts with a 500 mg dose on Day 1, followed by 250 mg once daily on Days 2 through 5.
  • 3-Day Course: Consists of 500 mg taken once daily for three consecutive days.
  • Single-Dose: For certain conditions, a single oral dose of 1,000 mg (1 gram) or 2,000 mg (2 grams) is prescribed.

Contextual Use and Administration Rules

Oral formulations can generally be taken with or without food; however, specific extended-release suspensions must be taken on an empty stomach (at least 1 hour before or 2 hours after a meal). A critical procedural constraint is the required 2-hour separation between the oral dose and any antacid.

For IV administration, the powder must be reconstituted and subsequently diluted to the specified concentration (e.g., 1 mg/mL or 2 mg/mL) and administered only as a slow infusion over a designated period. It is strictly prohibited from being given as an IV bolus or an intramuscular injection. Dosing for pediatric patients is calculated precisely based on body weight (mg/kg), rather than fixed adult doses. If a dose is missed, it should be taken as soon as possible, or skipped if close to the next scheduled dose time.

Recent Clinical Evidence

Research evidence / Overview of studies for Azipin

Evidence for Use in Community-Acquired Pneumonia and Bronchitis

Research exploring Azipin for lower respiratory tract infections, such as Community-Acquired Pneumonia (CAP) and Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB), primarily consists of Randomized Controlled Trials (RCTs) and systematic reviews (meta-analyses). These trials, conducted on adult and pediatric populations, examined clinical measurements and patient experiences.

Studies monitored outcomes like clinical response (how symptoms evolved) and bacteriological clearance measures (measurements related to clearing the responsible organism). For ABECB, research explored short-course regimens, examining clinical success (changes in respiratory outcomes) and, in some settings, the frequency of future episodes. Findings describe patterns observed in these studies, often derived from a comparison structure using another treatment rather than a non-treatment control.

Evidence for Use in Ear Infections (Acute Otitis Media)

Evidence for the use of Azipin in Acute Otitis Media (AOM) has been developed through short-course RCTs primarily involving pediatric patients. Researchers monitored outcomes related to functional imbalance, such as clinical response and measurement of middle ear symptom evolution.

Many trials used a comparison structure to monitor Azipin's measurements alongside those described for standard pediatric antibiotics. Trials reported measurements of clinical outcome success, often demonstrating patterns observed in the populations when compared relative to other widely studied treatments.

Summary of Evidence Gaps and Areas for Future Study

While research is ongoing, certain limitations remain. Much of the research structure relies on active-controlled trials, resulting in limited placebo-controlled evidence in many areas. Furthermore, the follow-up durations were limited across many pivotal studies, meaning long-term outcomes are not well characterized. Data for certain subgroups, particularly those with complex underlying conditions, often remain insufficient. The evidence base must continuously adapt to reports of evolving bacterial resistance patterns.

Key Studies & References

  1. A prospective, randomized, multicenter trial of azithromycin versus cefuroxime plus erythromycin for community-acquired pneumonia in hospitalized patients

Frequently Asked Questions (FAQ)

Common questions about Azipin (FAQ)

Q: How is Azipin different from other similar medicines I've heard of?

A: Official information describes Azipin's active ingredient, azithromycin, as belonging to the macrolide class of antibiotics, specifically categorized as an azalide. This structure is noted for giving it superior stability in the stomach and a long half-life. This long half-life is a property noted in regulatory documents for allowing the drug to concentrate in body tissues over time.

Q: How soon after starting Azipin might I notice a change?

A: Azithromycin is known for having a long half-life, meaning it remains in the body and concentrates in tissues for an extended period. While official sources do not specify the exact moment a patient will notice a change, this concentration property is a factor that supports its use in short treatment courses.

Q: Can Azipin be taken by older adults?

A: Regulatory documents do not prohibit use in older adults, but they advise caution. Official safety information highlights that older patients, particularly those with pre-existing heart conditions, may have an increased risk of the heart rhythm concerns associated with this medicine.

Q: How does Azipin affect sleep patterns?

A: Official product information does not explicitly list common side effects such as insomnia or excessive drowsiness. However, some documented side effects, such as dizziness and headache, are listed as potential effects on the nervous system.

Q: Does taking Azipin require any special monitoring or lab tests?

A: The need for special lab tests is typically based on an individual’s unique health profile or other medicines being taken. Official drug labels mention that the co-administration with certain medications, such as Digoxin and Warfarin, is associated with the need for close clinical monitoring. Caution is also advised for patients with existing impaired liver function.

Q: Is it normal to feel tired when first starting Azipin?

A: Tiredness or fatigue itself is not listed as one of the most common side effects in regulatory documents. However, common side effects like dizziness and headache are listed in official documents.

Q: How long does Azipin stay in your system after stopping?

A: Azipin's active ingredient has a notably long half-life, which supports its use in short treatment regimens. This property reflects that the medicine concentrates and persists in body tissues for an extended period after the last dose, often lasting for several days.

Q: What are the official approved uses of Azipin?

A: Regulatory sources approve Azipin (azithromycin) for the treatment of various bacterial infections. These officially approved indications commonly include lower respiratory tract infections (like Community-Acquired Pneumonia), middle ear infections (Acute Otitis Media), and certain sexually transmitted diseases and skin infections.

Q: Is Azipin typically used for short-term or long-term conditions?

A: Regulatory documents define the administration of Azipin in short courses. The medication is prescribed for specific bacterial infections using treatment durations that are typically one, three, or five days in length.

Q: Are there any major diet restrictions when using Azipin?

A: Most oral forms of Azipin can generally be taken with or without food. The key restriction noted in official labels is that regulatory documents describe the need for a two-hour separation between the oral dose and any antacids containing aluminum or magnesium.

Q: Can Azipin be taken with over-the-counter pain relievers like ibuprofen?

A: Official drug labels list specific medications that interact with Azipin, but they do not explicitly list common non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen as having a direct interaction that requires dose adjustment or avoidance.

Q: Is Azipin a controlled substance?

A: Azithromycin is a prescription-only drug used to treat infections. It is not classified as a controlled substance by regulatory bodies that govern drugs with high potential for abuse or dependence.

Q: Do I need to avoid driving while I am taking Azipin?

A: Azipin is associated with adverse reactions like dizziness and, less frequently, convulsions. If an individual experiences dizziness or other effects that affect mental clarity, the official product information describes that activities requiring complete mental alertness, such as driving or operating machinery, should be avoided while those symptoms occur.

Q: Are there specific vitamins or supplements that interact with Azipin?

A: Official drug labels focus on specific drug-to-drug interactions and do not provide an exhaustive list covering most common vitamins and supplements. Due to the potential for untested interactions, official guidance describes the importance of a healthcare provider being aware of all supplements and herbal remedies an individual is taking.

Q: Is Azipin described as having a risk of dependence or addiction?

A: No. Official drug classifications identify Azithromycin as an antibiotic and do not identify it as having any risk for dependence or addiction.

Q: Are there known interactions between Azipin and alcohol?

A: The official drug label does not list a direct chemical interaction between Azipin and alcohol. However, it is generally noted that alcohol consumption may worsen common side effects like nausea and dizziness. It is also noted that alcohol may interfere with recovery from an acute infection.

Q: Does Azipin interact with birth control pills?

A: Some official guidance suggests that antibiotics like Azipin may potentially reduce the effectiveness of estrogen-containing oral contraceptives in some women. Patients are generally advised to consult official prescribing information for the combined effects and whether alternative or additional contraceptive methods may be relevant during treatment.

Q: Does Azipin affect blood pressure?

A: Changes to blood pressure are not listed as a primary side effect in official adverse reaction reports. However, Azipin is associated with cardiovascular risks such as QT prolongation, which can lead to serious, irregular heart rhythms. Regulatory documents note that its use requires caution in patients with pre-existing heart conditions.

Q: Is Azipin used to treat anxiety or depression?

A: No. Azipin (azithromycin) is a macrolide antibiotic. It is approved only for treating bacterial infections and is not indicated for the treatment of mental health conditions like anxiety or depression.

Q: Does Azipin interact with herbal supplements like St. John's Wort?

A: The product label does not specifically address St. John’s Wort. Official guidance describes the importance of a patient discussing all herbal supplements they are taking with a healthcare provider, due to the potential for untested drug-supplement interactions.

Q: Is Azipin a new drug or has it been available for a while?

A: Azithromycin is not a new drug; it has been available for clinical use for several decades. The original brand-name version received its first major regulatory approval in the late 1980s.

Q: Are there any known risks of stopping Azipin suddenly?

A: The primary risk of stopping Azipin before completion relates to the infection itself. Regulatory warnings indicate that stopping the medication early may decrease the effectiveness of the treatment and increase the likelihood that bacteria will develop resistance to the antibiotic.

Q: Does Azipin cause any changes in vision?

A: For the oral formulations of Azipin, changes in vision are not listed as a common side effect. However, official information lists blurred vision and decreased vision as less common or rare side effects associated with the ophthalmic (eye drop) form of azithromycin.

Q: Is there a generic version of Azipin available?

A: Yes, the active ingredient, azithromycin, is widely available as a generic drug. Generic versions are approved by regulatory bodies after meeting the same quality and safety standards as the original brand-name medication.

Q: Has Azipin been researched in diverse patient populations?

A: Official research summaries confirm that Azipin has been studied in both adult and pediatric populations. However, regulatory documents also note that evidence regarding outcomes for certain subgroups of patients, particularly those with complex or specific underlying conditions, often remains insufficient.

Q: What are the common misunderstandings about how Azipin works?

A: Regulatory documents describe Azipin’s function as two-fold: it acts as a ribosomal inhibitor to stop bacterial growth, and it also functions as an immunomodulator to suppress excessive inflammation.

Q: Are there any specific symptoms that indicate I should stop taking Azipin?

A: Official safety information describes several severe and potentially life-threatening reactions. These include signs of a severe allergic reaction (like swelling or difficulty breathing), jaundice (yellowing of skin or eyes), and signs of a severe skin reaction (like blistering or peeling rash).

How should Azipin be stored and disposed of?

Official Storage and Disposal Requirements

Official regulatory documents define specific storage and disposal requirements for azithromycin products to maintain drug stability and safety.

Storage Conditions

  • Temperature: Store most forms (e.g., tablets, capsules, dry powder for suspension) at room temperature and protect them from excessive heat and moisture.
  • Light/Moisture: The medication must be kept away from direct sunlight.
  • Specific Forms: Unopened ophthalmic solution (eye drops) requires refrigeration (2°C to 8°C or 36°F to 46°F).
  • Child Safety: All forms must be stored out of the reach of children and pets.

Stability and Handling

  • Constituted Suspension: The oral liquid suspension, once mixed with water, has a very limited shelf life and must not be refrigerated. It must be used within a short, specified period (e.g., 12 hours).
  • Ophthalmic Solution: Once the bottle is opened, the solution has a defined in-use stability period (e.g., 14 days).

Disposal

  • Time-Limited Forms: Any remaining constituted oral suspension must be discarded after the designated time limit or after the course of treatment is completed.
  • The opened ophthalmic solution must be discarded after its in-use stability period has passed (e.g., 14 days).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Azipin found in:

A-Z Index: